Boyle MH, Furlong W, Feeny GW, et al. Reliability of the Health Utilities Index—Mark III used in the 1991 cycle 6 Canadian General Social Survey Health Questionnaire. Quality of Life Research 1995; 4:249–257.
Brodie M, Park WH. Active immunization against poliomyelitis. American Journal of Public Health 1936; 26:119–125.
Buffington J, Bell KM, LaForce FM. The Genesee Hospital Medical Staff. A target-based model for increasing influenza immunizations in private practice. Journal of General Internal Medicine 1991; 6:204–209.
Catlin G, Will P. The national population health survey: highlights of initial developments. Health Reports 1992; 4(3):313–319.
CDC (Centers for Disease Control and Prevention). Certification of poliomyelitis eradication in the Americas. Morbidity and Mortality Weekly Report 1994a; 54:720–722.
CDC. General recommendations on immunization. Recommendations of the advisory committee on immunization practices (ACIP). Morbidity and Mortality Weekly Report 1994b; 43(No. RR-1-4).
CDC. Summary of notifiable diseases, United States, 1994. Morbidity and Mortality Weekly Report 1994c; 43(53).
CDC. Influenza and pneumococcal vaccination coverage levels among persons aged greater than or equal to 65 years 1973–1993—United States 1995. Morbidity and Mortality Weekly Report 1995a; 44:506–507, 513–515.
CDC. Mass vaccination with oral poliovirus vaccine—Asia and Europe. Morbidity and Mortality Weekly Report 1995b; 44:234–236.
CDC. Progress towards global poliomyelitis eradication 1985–1994. Morbidity and Mortality Weekly Report 1995c; 44:273–275, 281.
CDC. Recommended childhood immunization schedule. Morbidity and Mortality Weekly Report 1995d:44:1–9.
CDC. National, state, and urban area vaccination coverage levels among children aged 19–35 months—United States, July 1996–June 1997. Morbidity and Mortality Weekly Report 1998; 47:108–116.
CDC. Recommended childhood immunization schedule—United States, 1999. Morbidity and Mortality Weekly Report 1999; 48:12–16.
Chatfield SN, Fairweather N, Charles I, et al. Construction of a genetically defined Salmonella typhi Ty2 aroa, aroc mutant for the engineering of candidate oral typhoid-tetanus vaccine. Vaccine 1992; 10:53–60.
Chen ST, Edsall G, Pell MM, et al. Timing of antenatal tetanus immunization for effective protection of the neonate. Bulletin of the World Health Organization 1983; 61:159–165.
Claassen I, Osterhaus A. The ISCOM structure as an immune-enhancing moiety: experience with viral systems. Research Immunology 1992; 143:531–541.
Coffman RL, Varkila K, Scott P, et al. Role of cytokines in the differentiation of CD4+ T-cell subsets in vivo. Immunology Review 1991; 123:189–207.
Commission on the Cost of Medical Care. The Economic Significance of the Prevention of Paralytic Poliomyelitis 1955–1961. Report of the Commission on the Cost of Medical Care 1964; 4:29–46.
Comroe JH, Dripps RD. Scientific basis for the support of biomedical science. Science 1976; 192:105–111.